Tonix Pharmaceuticals Holding Corp. (TNXP) financial statements (2021 and earlier)

Company profile

Business Address 28 MAIN STREET
CHATHAM, NJ 07928
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments77112525263538
Cash and cash equivalents77112525191938
Short-term investments    715 
Prepaid expense2      
Other undisclosed current assets93111121
Total current assets:88142626274639
Noncurrent Assets
Operating lease, right-of-use asset10
Property, plant and equipment9000000
Intangible assets, net (including goodwill)000000 
Intangible assets, net (excluding goodwill)000000 
Restricted cash and investments0000000
Other undisclosed noncurrent assets0  0000
Total noncurrent assets:10100011
TOTAL ASSETS:98152627284740
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5332273
Accounts payable5311131
Accrued liabilities  11142
Debt 0     
Due to related parties      0
Other undisclosed current liabilities52    (0)
Total current liabilities:10532273
Noncurrent Liabilities
Long-term debt and lease obligation10     
Operating lease, liability10
Liabilities, other than long-term debt   0000
Deferred revenue and credits0000
Other undisclosed noncurrent liabilities(1)      
Total noncurrent liabilities:10 0000
Total liabilities:11532273
Stockholders' equity
Stockholders' equity attributable to parent8892425254036
Common stock0000000
Additional paid in capital35522721218716714390
Accumulated other comprehensive income (loss)(0)(0)(0)(0)(0)(0)0
Accumulated deficit(268)(217)(188)(162)(141)(102)(54)
Total stockholders' equity:8892425254036
TOTAL LIABILITIES AND EQUITY:98152627284740

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:     0 
Operating expenses(51)(29)(26)(21)(39)(48)(28)
Other undisclosed operating loss     (0) 
Operating loss:(51)(29)(26)(21)(39)(48)(28)
Nonoperating income00000  
Investment income, nonoperating00000  
Gain on contract termination    0  
Other undisclosed income from continuing operations before equity method investments, income taxes   0000
Net loss:(50)(29)(26)(21)(39)(48)(28)
Other undisclosed net income attributable to parent      0
Net loss attributable to parent:(50)(29)(26)(21)(39)(48)(28)
Preferred stock dividends and other adjustments(1)(2)(3)    
Other undisclosed net loss available to common stockholders, basic(0)      
Net loss available to common stockholders, diluted:(52)(31)(29)(21)(39)(48)(28)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(50)(29)(26)(21)(39)(48)(28)
Other comprehensive income0000 00
Comprehensive loss:(50)(29)(26)(21)(39)(48)(28)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)(0)(0)0(0)0
Comprehensive loss, net of tax, attributable to parent:(50)(29)(26)(21)(39)(48)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: